To provide for the development and dissemination of best practices to ensure that visually-impaired and blind individuals in the United States have safe, consistent, reliable, and independent access to the information in prescription drug labeling.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Prescription Drug Labeling Promotion Act of 2012''.
SEC. 2. ACCESSIBILITY OF INFORMATION IN PRESCRIPTION DRUG LABELING BY VISUALLY-IMPAIRED AND BLIND CONSUMERS.
(a) Establishment of Working Group.-- (1) In general.--The Secretary of Health and Human Services (in this section referred to as the ``Secretary'') shall establish a working group (in this section referred to as the ``working group'') to develop and promulgate guidance constituting best practices on access to prescription drug labeling for the visually impaired. (2) Members.--The working group shall include representatives of national organizations representing blind and visually impaired individuals, national organizations representing the elderly, and industry groups representing stakeholders, including pharmacists, who would be impacted by such best practices. Representation within the working group shall be divided equally between consumer and industry advocates. (3) Guidance on best practices.--The working group shall promulgate, not later than 1 year after the date of the enactment of this Act, guidance on best practices for pharmacies to ensure that blind and visually impaired individuals have safe, consistent, reliable, and independent access to the information in the labeling of prescription drugs. Such guidance shall be made available...